It is now a decade since the World Trade Organization (WTO) adopted the “Declaration on the TRIPS Agreement and Public Health” at its 4th Ministerial Conference in Doha. Many anticipated that these actions would lead nations to claim compulsory licenses (CLs) for pharmaceutical products with greater regularity. A CL is the use of a patented innovation that has been licensed by a state without the permission of the patent title holder. Skeptics doubted that many CLs would occur, given political pressure against CL activity and continued health system weakness in poor countries. The subsequent decade has seen little systematic assessment of the Doha Declaration's impact.We assembled a database of all episodes in which a CL was publically ente...
Startling numbers of people die every day because they do not have access to essential medicines and...
The conflict between patents and public health has been a long-standing concern. The current COVID-1...
Millions of people, particularly in low- and middle-income countries, lack access to effective pharm...
It is now a decade since the World Trade Organization (WTO) adopted the “Declaration on the TRIPS Ag...
In response to concerns that patent protection for pharmaceuticals negatively affected world health,...
The World Health Organization has once declared antiretroviral therapy a state of global emergency. ...
401-413Adhering to the TRIPS Agreement in the pharmaceutical sector poses several questions before d...
The AIDS crisis in the developing world has become a priority for international collaboration. The c...
The aim of this thesis is to provide an insight into the potential effects that follow the use of co...
357-363While the TRIPS Agreement provides for the patenting of drugs, it also provides for compulso...
The Trade Related Aspects of Intellectual Property Rights (TRIPS) Agreement of 1994, an outcome of t...
The Trade-related Aspects of Intellectual Property Rights (TRIPS) Agreement went into effect for Wor...
In 1995, the World Trade Organization (WTO) linked intellectual property protection with the trade b...
The public health crisis related to HIV/AIDS, Tuberculosis and Malaria, was the starting point for t...
International audienceWhile compulsory licensing (CL) is described in the TRIPS agreement as flexibi...
Startling numbers of people die every day because they do not have access to essential medicines and...
The conflict between patents and public health has been a long-standing concern. The current COVID-1...
Millions of people, particularly in low- and middle-income countries, lack access to effective pharm...
It is now a decade since the World Trade Organization (WTO) adopted the “Declaration on the TRIPS Ag...
In response to concerns that patent protection for pharmaceuticals negatively affected world health,...
The World Health Organization has once declared antiretroviral therapy a state of global emergency. ...
401-413Adhering to the TRIPS Agreement in the pharmaceutical sector poses several questions before d...
The AIDS crisis in the developing world has become a priority for international collaboration. The c...
The aim of this thesis is to provide an insight into the potential effects that follow the use of co...
357-363While the TRIPS Agreement provides for the patenting of drugs, it also provides for compulso...
The Trade Related Aspects of Intellectual Property Rights (TRIPS) Agreement of 1994, an outcome of t...
The Trade-related Aspects of Intellectual Property Rights (TRIPS) Agreement went into effect for Wor...
In 1995, the World Trade Organization (WTO) linked intellectual property protection with the trade b...
The public health crisis related to HIV/AIDS, Tuberculosis and Malaria, was the starting point for t...
International audienceWhile compulsory licensing (CL) is described in the TRIPS agreement as flexibi...
Startling numbers of people die every day because they do not have access to essential medicines and...
The conflict between patents and public health has been a long-standing concern. The current COVID-1...
Millions of people, particularly in low- and middle-income countries, lack access to effective pharm...